A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines. However, the usefulness of traditional live-attenuated ...
Cancer therapies sometimes involve drugs that mediate the breakdown of specific intracellular proteins that participate in cancer formation and proliferation. Proteolysis-targeting chimeras or PROTACs ...
NEW HAVEN, Conn., June 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
New York, USA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsight DelveInsight’s PROTAC Market Insights ...
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that offer a promising therapeutic strategy against hard-to-treat diseases. Unlike traditional small molecule inhibitors, ...
Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.
Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein. Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback